Expression of Tryptophan 2,3-Dioxygenase and Production of Kynurenine Pathway Metabolites in Triple Transgenic Mice and Human Alzheimer's Disease Brain
暂无分享,去创建一个
Gilles J. Guillemin | Bruce J. Brew | B. Brew | C. Lim | G. Guillemin | K. Cullen | J. Nicolazzo | S. Bao | Chai K. Lim | Karen M. Cullen | R. Chung | Joseph A. Nicolazzo | Roger Chung | Wei Wu | Li Wen | Roger Stankovic | Shisan S. Bao | R. Stankovic | Wei Wu | Li Wen
[1] B. Brew,et al. Quinolinic acid in the pathogenesis of Alzheimer's disease. , 2003, Advances in experimental medicine and biology.
[2] D. Keskin,et al. Indoleamine 2,3-dioxygenase, immunosuppression and pregnancy. , 2002, Journal of reproductive immunology.
[3] D. Fuchs,et al. Tryptophan degradation and immune activation in Alzheimer's disease , 2000, Journal of Neural Transmission.
[4] George Perry,et al. Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease , 2010, Redox report : communications in free radical research.
[5] O. Brown,et al. Tryptophan metabolism through the kynurenine pathway in rat brain and liver slices. , 2000, Free radical biology & medicine.
[6] O. Takikawa,et al. Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. , 1988, The Journal of biological chemistry.
[7] P. Mcgeer,et al. Local neuroinflammation and the progression of Alzheimer’s disease , 2011, Journal of NeuroVirology.
[8] B. Brew,et al. Mass spectrometric detection of quinolinic acid in microdissected Alzheimer's disease plaques , 2007 .
[9] Gilles J. Guillemin,et al. The Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons , 2009, PloS one.
[10] B. Brew,et al. Expression of the kynurenine pathway enzymes in human microglia and macrophages. , 2003, Advances in experimental medicine and biology.
[11] N. Braidy,et al. Effects of Kynurenine Pathway Inhibition on NAD+ Metabolism and Cell Viability in Human Primary Astrocytes and Neurons , 2011, International journal of tryptophan research : IJTR.
[12] R. Beninger,et al. Quinolinate-induced cortical cholinergic damage: modulation by tryptophan metabolites , 1990, Brain Research.
[13] C. Colton,et al. Activated human microglia produce the excitotoxin quinolinic acid , 1997, Neuroreport.
[14] R. Schwarcz,et al. Kynurenine 3-Monooxygenase Inhibition in Blood Ameliorates Neurodegeneration , 2011, Cell.
[15] B. Brew,et al. Characterization of the kynurenine pathway in human oligodendrocytes , 2007 .
[16] G. Oxenkrug,et al. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. , 1969, Lancet.
[17] F. Hirata,et al. Indoleamine 2,3-dioxygenase. Purification and some properties. , 1978, The Journal of biological chemistry.
[18] R. Rubin. Adrenal cortical activity changes in manic-depressive illness. Influence on intermediary metabolism of tryptophan. , 1967, Archives of general psychiatry.
[19] S. Weis,et al. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder , 2006, Brain Research.
[20] G. Guillemin,et al. Proinflammatory cytokine interferon‐γ increases induction of indoleamine 2,3‐dioxygenase in monocytic cells primed with amyloid β peptide 1–42: implications for the pathogenesis of Alzheimer’s disease , 2009, Journal of neurochemistry.
[21] R. Yolken,et al. Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia , 2004, Neurobiology of Disease.
[22] P. Ricciardi-Castagnoli,et al. Regulation of the Kynurenine Metabolic Pathway by Interferon‐γ in Murine Cloned Macrophages and Microglial Cells , 1996, Journal of neurochemistry.
[23] D. Kranz,et al. Neuronal localization of indoleamine 2,3-dioxygenase in mice , 2005, Neuroscience Letters.
[24] M. Mattson,et al. Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.
[25] D. Nutt,et al. Tryptophan metabolism in the central nervous system: medical implications , 2006, Expert Reviews in Molecular Medicine.
[26] Gilles J Guillemin,et al. Characterization of the Kynurenine Pathway in Human Neurons , 2007, The Journal of Neuroscience.
[27] R. Pellicciari,et al. Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease , 2009, Amino Acids.
[28] G. Melillo,et al. The Tryptophan Catabolite Picolinic Acid Selectively Induces the Chemokines Macrophage Inflammatory Protein-1α and -1β in Macrophages1 , 2000, The Journal of Immunology.
[29] O. Takikawa. Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism. , 2005, Biochemical and biophysical research communications.
[30] D. Munn,et al. Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism , 1999, The Journal of experimental medicine.
[31] Cheng-Hsien Lu,et al. Elevated basal cortisol level predicts lower hippocampal volume and cognitive decline in Alzheimer’s disease , 2009, Journal of Clinical Neuroscience.
[32] S. Mizuno,et al. Tryptophan 2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice , 2009, Molecular Brain.
[33] Identification and expression of alpha cDNA encoding human 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase (ACMSD): a key enzyme for the tryptophan-niacine pathway and quinolinate hypothesis. , 2002, Advances in experimental medicine and biology.
[34] B. Brew,et al. Expression of indoleamine 2,3‐dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons , 2005, Glia.
[35] T. Stone,et al. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. , 1981, European journal of pharmacology.
[36] E. Major,et al. Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. , 1997, The Biochemical journal.
[37] H. Rammensee,et al. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. , 2008, Blood.
[38] R. Beninger,et al. Picolinic acid modulates kainic acid-evoked glutamate release from the striatum in vitro , 1993, Brain Research.
[39] S. Mandel,et al. Gene expression analysis in N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R‐apomorphine , 2001, Journal of neurochemistry.
[40] G. Guillemin. Quinolinic acid, the inescapable neurotoxin , 2012, The FEBS journal.
[41] G. Melillo,et al. Immunobiology of picolinic acid. , 1996, Advances in experimental medicine and biology.
[42] Toshikazu Nakamura,et al. Identification and characterization of novel variants of the tryptophan 2,3-dioxygenase gene: Differential regulation in the mouse nervous system during development , 2009, Neuroscience Research.
[43] C. Uyttenhove,et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase , 2012, Proceedings of the National Academy of Sciences.
[44] G. Melillo,et al. The tryptophan catabolite picolinic acid selectively induces the chemokines macrophage inflammatory protein-1 alpha and -1 beta in macrophages. , 2000, Journal of immunology.
[45] Y. Huang,et al. Peripheral lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1β and anti-inflammatory IL-10 cytokines , 2009, Brain, Behavior, and Immunity.
[46] G. Oxenkrug. Interferon-gamma-inducible kynurenines/pteridines inflammation cascade: implications for aging and aging-associated psychiatric and medical disorders , 2010, Journal of Neural Transmission.
[47] Y. Egashira,et al. Identification and expression of alpha cDNA encoding human 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase (ACMSD): a key enzyme for the tryptophan-niacine pathway and quinolinate hypothesis. , 2002, Advances in experimental medicine and biology.
[48] B. Brew,et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection , 2001, Journal of neurochemistry.
[49] O. Hayaishi,et al. The oxygenated form of L-tryptophan 2,3-dioxygenase as reaction intermediate. , 1970, The Journal of biological chemistry.
[50] B. Brew,et al. Indoleamine 2,3 dioxygenase and quinolinic acid Immunoreactivity in Alzheimer's disease hippocampus , 2005, Neuropathology and applied neurobiology.